60 DEGREES PHARMACEUTICALS, INC. SXTP
Description of Business.
We are a specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that has been on the market since late 2019. Currently, 60P's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2018 |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | $607.6K | $253.6K | $223.2K | — | — |
| Cost of revenue | $781.7K | $384.8K | $474.6K | $432.4K | — | — |
| Gross profit | $223.8K | $222.8K | -$221.0K | -$209.2K | — | — |
| R&D | $2.1M | $5.0M | $691.8K | $525.6K | — | — |
| SG&A | $6.3M | $5.0M | $4.2M | $1.3M | — | — |
| Total operating expenses | $8.4M | $10.0M | $4.9M | $1.8M | — | — |
| Operating income | -$7.8M | -$9.7M | -$5.2M | -$1.8M | — | — |
| Interest expense | $7.8K | $7.9K | $2.3M | $4.0M | — | — |
| Pre-tax income | -$7.4M | -$8.0M | -$3.8M | -$6.2M | — | — |
| Income tax | $0 | $0 | $250 | $500 | — | — |
| Net income | -$7.4M | -$7.9M | -$3.8M | -$6.2M | — | — |
| EPS, basic | -11.73 | -74.17 | -59.18 | -2.61 | — | — |
| EPS, diluted | -11.73 | -74.17 | -59.18 | -2.61 | — | — |
| Shares, diluted (wtd. avg.) | 670,211 | 113,665 | 66,314 | 2.4M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2018 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $1.5M | $1.7M | $2.1M | $264.9K | $115.4K | — |
| Short-term investments | $1.2M | $1.7M | — | — | — | — |
| Receivables | $509.6K | $486.7K | $231.3K | $46.0K | — | — |
| Inventory | $656.9K | $442.8K | $466.2K | $518.6K | — | — |
| Total current assets | $4.9M | $5.4M | $7.2M | $1.1M | — | — |
| Property, plant and equipment | $246.4K | $149.8K | $57.8K | $21.3K | — | — |
| Other intangibles | $224.4K | $157.1K | $227.3K | $164.3K | — | — |
| Total assets | $5.4M | $5.8M | $7.8M | $1.3M | — | — |
| Accounts payable | $1.5M | $1.0M | $506.2K | $758.7K | — | — |
| Short-term debt | $8.8K | $8.8K | $8.8K | $200.0K | $979.3K | $3.0M |
| Total current liabilities | $1.8M | $1.7M | $2.8M | $23.9M | — | — |
| Long-term debt | $144.0K | $147.1K | $150.0K | — | — | — |
| Total liabilities | $2.0M | $1.8M | $3.0M | $25.4M | — | — |
| Retained earnings | -$47.9M | -$40.5M | -$32.6M | -$28.8M | — | — |
| Total equity | $3.5M | $4.0M | $4.8M | -$24.1M | -$18.2M | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2018 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$6.8M | -$5.6M | -$4.5M | -$1.0M | — | — |
| Depreciation and amortisation | $43.3K | $11.7K | $21.2K | $27.6K | — | — |
| Stock-based compensation | — | — | $212.6K | — | — | — |
| Capital expenditure | $139.9K | $103.8K | $57.6K | — | — | — |
| Investing cash flow | $254.9K | -$1.9M | -$115.9K | -$60.1K | — | — |
| Financing cash flow | $6.4M | $7.1M | $6.5M | $1.2M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001554855-26-000467.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $223.2K | $253.6K | $607.6K | $1.0M |
| Gross profit | — | — | -$209.2K | -$221.0K | $222.8K | $223.8K |
| Net income | — | — | -$6.2M | -$3.8M | -$7.9M | -$7.4M |
Recent filings and events
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Other event Item 8.01
- Other event Item 8.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |